ImmunoVaccine Technologies‘ DepoVax, depot vaccine formulation, has shown positive results in pre-clinical phase. The patented product has achieved single-dose efficacy in the treatment of cancer and other infectious disease vaccine models. Based on a new approach that uses liposomes which encapsulate a target antigen and adjuvant, DepoVax relies on a hydrophobic oil carrier that enhances vaccine induced cell-mediated immunity significantly.